Efficacy evaluation of intraoperative esketamine in preventing postoperative depression-- A prospective, double-blind, randomized, controlled trial

Efficacy evaluation of intraoperative subclinical dose of esketamine in preventing depression after cesarean section

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200061154

Enrollment

Unknown

Registered

2022-06-15

Start date

2022-06-01

Completion date

Unknown

Last updated

2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cesarean section

Interventions

test group:Esketamine 0.25mg/kg diluted to 10ml with normal saline for slow intravenous injection

control group:Normal saline 10ml slow intravenous injection

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. ASA I-II grade; 2. Elective cesarean section; 3. The proposed anesthesia method is spinal anesthesia.

Exclusion criteria

Exclusion criteria: 1. Body mass index>= 40kg/m^2; 2. Contraindications and allergies to the test drug; 3. History of hallucinations; 4. History of drug abuse; 5. History of mental illness; 6. Chronic pain; 7. Intraspinal anesthesia contraindications.

Design outcomes

Primary

Measure	Time frame
Edinburgh Postnatal Depression Scale score;	—

Secondary

Measure	Time frame
Pain Scoring: Numerical Scale;	—

Countries

China

Contacts

Public ContactTianwu Shi

tianwu828@163.com+86 13866185478

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026